Pulmonx (NASDAQ:LUNG) Issues Earnings Results

Pulmonx (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06, FiscalAI reports. The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $20.78 million. Pulmonx had a negative return on equity of 73.21% and a negative net margin of 61.91%. Pulmonx updated its FY 2025 guidance to EPS.

Pulmonx Trading Down 18.9%

Pulmonx stock opened at $1.59 on Friday. Pulmonx has a 52-week low of $1.47 and a 52-week high of $9.37. The company has a market cap of $64.79 million, a P/E ratio of -1.13 and a beta of 0.44. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. The business has a 50-day simple moving average of $1.72 and a two-hundred day simple moving average of $2.39.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research note on Wednesday, October 8th. Lake Street Capital lowered their price target on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, October 28th. Wall Street Zen downgraded Pulmonx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Piper Sandler cut shares of Pulmonx from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $2.50 in a research note on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pulmonx has an average rating of “Hold” and a consensus target price of $6.81.

Institutional Trading of Pulmonx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of Pulmonx during the 2nd quarter valued at $149,000. Norges Bank bought a new position in shares of Pulmonx during the 2nd quarter valued at approximately $392,000. Jane Street Group LLC raised its stake in Pulmonx by 3,328.7% during the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock worth $230,000 after acquiring an additional 86,046 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after purchasing an additional 407,971 shares in the last quarter. 91.04% of the stock is owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.